Using Genetically Modified Viruses to Target and Treat Cancer

A method for creating a modified vaccinia virus that safely hunts down and kills tumor cells while leaving healthy tissue alone.

What it covers

The patent describes a modified vaccinia virus engineered to act as a precision cancer treatment. By disabling three specific genetic components—the thymidine kinase (TK) gene, the hemagglutinin (HA) gene, and the F3 locus—the virus loses its ability to replicate efficiently in healthy cells but thrives in the environment of a tumor. The researchers can also insert extra genetic instructions into these modified sites to force the virus to produce therapeutic proteins, such as antibodies or transporters, directly inside the cancer site. This allows the virus to serve as both a delivery vehicle and a factory for anti-cancer drugs.

What it doesn't cover

• —Does not cover unmodified, wild-type vaccinia viruses found in nature.
• —Does not cover gene therapies that do not utilize the specific triple-inactivation (TK, HA, and F3) described.
• —Does not cover viral therapies that replicate equally well in healthy and cancerous tissues.

The clever bit

The innovation lies in the triple-knockout strategy; by inactivating the F3 locus alongside the standard TK and HA genes, the researchers achieved a specific safety profile that prevents the virus from causing widespread systemic toxicity while maintaining its ability to home in on immunoprivileged tumor environments.

Why it matters

This technology represents a significant step in oncolytic virotherapy, an approach that turns viruses into allies against cancer. By making the virus safer for the patient, it allows for systemic administration rather than direct injection into a tumor. This is a core component of Genelux Corporation's pipeline for developing targeted cancer therapeutics.

Real-world examples

• 1.Genelux Corporation's GL-ONC1 therapeutic candidate
• 2.Oncolytic viral therapy clinical trials